ACM
MGNX icon

AlphaCrest Capital Management’s MacroGenics MGNX Stock Holding History

AlphaCrest Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-28,386
Closed -$456K – 1344
2021
Q4 		$456K Sell
28,386
-8,900
-24% -$168K 0.02% 1133
2021
Q3 		$781K Buy
+37,286
New +$898K 0.04% 726

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCrest Capital Management's MGNX Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of MacroGenics (MGNX) in Q1 2022, closing a stake of 28,386 shares — an estimated $456K sold.

AlphaCrest Capital Management first reported a position in MGNX in Q3 2021 and held it in 2 quarters. The position peaked at $781K in Q3 2021. 144 funds tracked by Wall St. Rank hold MGNX as of Q1 2022.

  • AlphaCrest Capital Management reported no remaining MacroGenics position as of Q1 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 28,386 MacroGenics shares in Q1 2022, an estimated $456K.
  • AlphaCrest Capital Management first reported a position in MacroGenics in Q3 2021 and held it in 2 quarters.
  • AlphaCrest Capital Management's MacroGenics position peaked at $781K in Q3 2021.
  • 144 funds tracked by Wall St. Rank held MacroGenics as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.